

Australasian Gastrointestinal Pathology Society

4th Annual Scientific Meeting

27 & 28 October 2018

Clinical Education Centre, Auckland Hospital, New Zealand

www.agps.org.nz



Pouchitis and Cuffitis

A bloody mess

Sze-Lin Peng

Colorectal Surgeon

Counties Manukau District Health Board






COUNTIES
MANUKAU
HEALTH

 Healthy Together









Ileal-pouch anal anastomosis

Proctocolectomy with J-pouch Reconstruction Stage 1




Types of pouch





The anatomy of a pouch




A = efferent limb

B= pouch

C = afferent limb


D= anastomosis



Pouch function and life span

- 4-8 motions a day, 1-3 motions at night
- Continent
- Good QOL at 12 months
- Dietary modification + loperamide
- Fecal incontinence up to 40-50% in 20-30yrs
- 15% pouch failure at median 6 yrs
 - Loop ileostomy or pouch excision
 - Even higher in Crohn's disease 25-100%



Symptoms



Clinical approach

- History
 - Review previous scopes, histology and operation notes
 - Toxins
- Examination+ Biopsies
 - Endoscopy
 - Examination under anaesthesia
- Investigations
 - Bloods
 - MRI/ CT
 - Stool cultures


Standardised pouchoscopy report



Pouchitis

- Most common long term complication
- Cumulative incidence 20-50% (1 – 5 yrs)
- 40% occur in the 1st 12 months post ileostomy closure
- 40% single episode only
- 5-20% end up with refractory disease
- Risk factors
 - Extensive UC, PSC, pANCA +ve, non-smoker, young, regular NSAIDs, obesity, backwash ileitis, genetic polymorphisms

Pathogenesis



Pouch disease activity index (PDAI)

Histology useful in clinical practice

- Detection of specific pathogens (such as CMV, Candida)
- Granulomas
- Ischemia
- Mucosal prolapse
- Dysplasia

Chronic histological may reflect 'normal' adaptive changes to stasis

Criteria	Score
Clinical	
Stool frequency	
Usual postoperative stool frequency	0
1-2 stool/d > postoperative usual	1
3 or more stool/d > postoperative usual	2
Rectal bleeding	
None or rare	0
Present daily	1
Fecal urgency or abdominal cramps	
None	0
Occasional	1
Usual	2
Fever (temperature > 37.8 °C)	
Absent	0
Present	1
Endoscopic findings	
Edema	1
Granularity	1
Friability	1
Loss of vascular pattern	1
Mucous exudates	1
Ulceration	1
Histological findings - acute histological inflammation	
Polymorphonuclear leucocyte infiltration	
Mild	1
Moderate without crypt abscess	2
Severe with crypt abscess	3
Ulceration per low-power field (mean)	
< 25% / 25%-50% / > 50%	1/2/3
Total pouchitis disease activity index (max 18) pouchitis ≥ 7	

Classification of pouchitis

Duration

- acute (< 4 weeks)
- Relapsing (≥ 3 acute episodes in 12 months)
- chronic (≥ 4 weeks)

Antibiotic response

- Responsive
- Dependent
- Refractory


Cause

- Idiopathic
- Secondary

Treatment

- Antibiotics initial treatment
 - Ciprofloxacin 500mg BD or Metronidazole 400mg TDS po 14 days
- <http://www.e-guide.ecco-ibd.eu/algorithm/pouchitis>

- Escalating therapies (budesonide, biologics..)
 - ? Reducing pouch failure incidence
 - Crohns still leading cause of pouch failure




CMV

- May not be always pathogenic
- Probably uncommon cause of pouchitis
- Clinical features
 - Fever
 - Prepouch ileal ulcerations
 - Immunosuppression more common
- Histology
 - Immunohistochemistry/ PCR
 - Inclusion bodies not always present
 - Biopsies taken from ulcers more likely to contain CMV DNA
- Treatment
 - 2-4 week course of ganciclovir
 - Repeat endoscopy should be considered to confirm CMV eradication/ mucosal healing, especially when features of Crohns i.e deep mucosal ulcerations and/or prepouch ileitis
- Prognosis
 - Most have normal pouch function after treatment for CMV

Cuffitis

- Retained columnar epithelium 1.5-2cm
- UC or UC-like inflammatory process vs *other* (ischaemia/ surgical sepsis/ dysplasia)
- Clinical
 - Can co-exist with pouchitis
 - > bloody
 - Toxic megacolon, fulminant colitis, preoperative biologic use
- Usual treatment is topical ASA, steroids →→ biologics
 - Responsive
 - Dependent
 - Refractory up to 50% - 1/3 Crohns, 1/3 surgical complications,
 - Pouch failure around 10%



Summary

- Pouchitis and cuffitis are challenging conditions to diagnose and treat
- 1st line rx for pouchitis = antibiotics
- 1st line rx for cuffitis = immunomodulators
- Multidisciplinary approach essential
 - Surgical anatomy
 - Complex medical pathogenesis
 - Balance with function and quality of life